<< Back To Prostate Cancer News
  Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and...  
 

Cancer Weekly (Published: Tuesday, May 13, 2014, Received: Wednesday, May 7, 2014, 7:40:44 PM CDT)
Pharmaceutical Companies
Word Count: 361
 

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer

By a News Reporter-Staff News Editor at Cancer Weekly -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer (CRPC) (see also Pharmaceutical Companies).

Top-line survival results indicate the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival (OS) in men with metastatic CRPC, compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p-value 0.207).

"We are disappointed with these results. Addressing treatment resistance is critical in the fight against cancer. We are working with OncoGenex to more fully understand these data," said Michael Hayden, MD, president of global R&D and chief scientific officer at Teva Pharmaceutical Industries Ltd.

The adverse events (AEs) observed for custirsen were similar to its known AE profile.

Full efficacy and safety data from SYNERGY will be submitted for presentation at an upcoming scientific conference. About Custirsen Custirsen is an experimental drug that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration. By inhibiting clusterin, custirsen is designed to alter tumor dynamics, slowing tumor growth and resistance to partner treatments, so that the benefits of therapy, including survival, may be extended.

Keywords for this news article include: Pharmaceutical Companies, Teva Pharmaceutical Industries Ltd., Cancer, Therapy, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

 
(c) 2014 Cancer Weekly via NewsRx.com
 
Companies
Teva Ooo
Teva Pharmaceutical Industries Limited
OncoGenex Pharmaceuticals Inc.
Teva Pharmaceutical Industries Limited
Industries
Pharmaceuticals
Subjects
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Pharmaceutical Development
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
                  Drug Testing and Approval Process
      Treatments and Therapies
            Medicinal Drugs
                  Drug Testing and Approval Process

 

Facebook - UsToo.org  Twitter - UsToo.org  LinkedIn - UsToo.org Inspire prostate cancer discussions  UsToo.org 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

 
Copyright 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.